Joon Won Jeong

Joon Won Jeong is a Principal Scientist at Exelixis, with a notable career in medicinal chemistry, drug discovery, and management. Prior experience includes a Principal Scientist role at Carmot Therapeutics, overseeing a PhD chemist and CRO staff while leading multiple drug discovery programs, including the development of covalent inhibitors for KRAS G12C, resulting in Lumakras's approval in 2021. Previous roles at Exelixis involved developing RORg antagonists and PI3Kg inhibitors for various diseases. Early career contributions included a postdoctoral position at the University of California, Irvine, focusing on natural alkaloid synthesis and a senior researcher role in the Korean Research Institute of Chemical Technology, developing PDE4 inhibitors for asthma and COPD. Joon Won Jeong holds a Ph.D. and B.S. in Chemistry from the Korea Advanced Institute of Science and Technology.